Biopharmaceutical Excipients Manufacturing Market

Market Outlook

The global biopharmaceutical excipients manufacturing market, valued at USD 3.3 billion in 2025, is projected to reach USD 3.6 billion in 2026 and USD 6.3 billion by 2035, representing a CAGR of 6.4% during the forecast period 2026 to 2035.

Market Report: Key Takeaways

Market Size & Trends

• In terms of scale of operation, the commercial segment holds the highest share (nearly 90%) of the market.
• With respect to type of modality, the antibodies segment dominates the current market.
• Based on the type of excipients, buffering agents capture the largest share of the market; this trend is unlikely to change in the future.
• In terms of chemical components, carbohydrates hold the highest market share.
• Based on the company size, large and very large players are likely to capture the largest share of the market in 2026.
• In terms of source of manufacturing, in house segment holds the highest market share.
• With respect to end user, the pharmaceutical companies segment dominates the current market.
• In terms of geographical regions, Europe holds the highest market share (35%).

Market Introduction

Over the years, the rising popularity of biologics has led to a paradigm shift in the healthcare industry. In the last decade alone, the annual number of approvals of biopharmaceuticals (including monoclonal antibodies, recombinant proteins, vaccines and gene therapies) by the USFDA has steadily increased, with biologics making up over 40% of all new drug approvals. As of October 2024, there were over 12,700 biological pharmaceutical products under clinical investigation worldwide, highlighting the extent of innovation in this field. Given their distinct benefits over small molecules, including higher efficacy, precise target specificity, and favorable safety, biologics are expected to continue driving advances in treatment for oncology, autoimmune disorders, rare diseases, and genetic conditions.

Despite these benefits, biologics are structurally complex and inherently less stable than small molecules, making them prone to physical (aggregation, precipitation, denaturation) and chemical (oxidation, deamidation, hydrolysis) degradation. To address such limitations, a range of biopharmaceutical excipients, including sugars (sucrose and trehalose), amino acids (arginine), surfactants (polysorbates), and polymeric agents (PEGs) are utilized to stabilize formulations, enhance solubility, control pH and tonicity, and improve overall bioavailability. In fact, over 70% of marketed biologics rely on polysorbates as stabilizing agents, while bulking agents, antioxidants, and preservatives expand their functional value. Moreover, excipients have become vital in enabling advanced drug product formats, including lyophilized vials, prefilled syringes, and ready to use liquid formulations.

Emerging innovations, particularly in lipid-based excipients for mRNA vaccines and therapeutics, are further expanding the excipient landscape. Coupled with the rising trend in outsourcing and growing regulatory support for novel excipients, the use of biopharmaceutical excipients is poised for sustained market growth during the forecast period.

Market Segmentation

Based on the research, we have segmented the biopharmaceutical excipients manufacturing market into scale of operation, type of modality, type of excipients, chemical components, company size, source of manufacturing, end user and geographical regions.

By Scale of Operation

• Preclinical / Clinical Scale
• Commercial Scale

By Type of Modality

• Antibodies
• Vaccines
• Cell and Gene Therapies
• Proteins / Peptides
• Other Biologics

By Type of Excipients

• Buffering Agents
• Lyoprotectant Agents
• Solubilizers and Surfactants
• Tonicity Agents
• pH Adjusting Agents
• Others

By Chemical Components

• Carbohydrates
• Polymers
• Polyols
• Proteins / Amino Acids
• Others

By Company Size

• Small Players
• Mid-sized Players
• Large and Very Large Players

By Source of Manufacturing

• In-house
• Outsourcing

By End User

• Contract Manufacturers
• Pharmaceutical Companies
• Hybrid Players

By Geographical Regions

• North America
  • US
  • Canada

• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe

• Asia-Pacific
  • China
  • India
  • South Korea
  • Japan
  • Rest of Asia-Pacific

• Middle East and Africa
  • Saudi Arabia
  • UAE
  • Egypt

• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America

Biopharmaceutical Excipients Manufacturing Market Key Insights

What Factors Contribute to Biopharmaceutical Excipients Manufacturing Market Trends?

• Launch of Endotoxin Controlled Excipients: Endotoxin controlled excipients refer to high-purity pharmaceutical ingredients that are stringently monitored and manufactured to ensure exceptionally low levels of endotoxins, thereby aligning with the evolving regulatory and quality standards for advanced biologics and parenteral products. Notably, the demand for these excipients has surged in recent years, primarily driven by the increased adoption of biologics, cell therapies, and other sensitive biomedical applications where the presence of endotoxins can lead to serious safety concerns, including pyrogenic reactions. However, it is worth mentioning that these excipients are particularly crucial in injectable therapeutics, vaccines, medical devices, and 3D bioprinting workflows, where any compromise in excipient purity could impact both product safety and efficacy.
• Increase in Expansion Activity: Several stakeholders in this domain have undertaken initiatives to expand their respective facilities / capabilities, in order to enhance their offerings. Most of the expansions reported in this domain were focused on additions of new facilities. This is primarily driven by the increasing demand for high-quality, specialized excipients required for advanced biopharmaceutical formulations, including biologics, gene therapies, and vaccines. This has led to manufacturers investing in state-of-the-art facilities that adhere to stringent good manufacturing practice (GMP) standards to ensure product quality, safety, and regulatory compliance.

Recent Developments in Biopharmaceutical Excipients Manufacturing Market

Industry Experts on Biopharmaceutical Excipients Manufacturing Market

The market for biopharmaceutical excipients manufacturing has a transformative future and is likely to remain progressive in the future.

Jeannette M. Wetzel (Biopharma Sales Director of DFE Pharma), stated that, “One of the major challenges in this domain is the limited availability of necessary investment required to support capacity expansion. Stringent regulations related to quality of biopharmaceutical excipients poses another key concern for biopharmaceutical excipient developers.”

Market Share Insights

Which Scale of Operation Accounts for the Largest Share of Biopharmaceutical Excipients Manufacturing Market?

This segment highlights the distribution of market value for biopharmaceutical excipients across various scales of operation, such as preclinical / clinical and commercial scale.

Currently, the commercial scale subsegment captures majority (close to 90%) of the biopharmaceutical excipients manufacturing market share. This dominance stems from the successful transition of a growing number of biologic therapies, particularly monoclonal antibodies, recombinant proteins and vaccines, from clinical development into full-scale commercial manufacturing. Unlike preclinical and clinical phases, where excipient demand is limited in volume and highly variable, commercial production requires consistent, large-volume supply of high-purity excipients like sucrose, surfactants, buffers and stabilizers. This is mainly to support continuous large scale batch manufacturing of biologics which creates a predictable, high-value revenue stream for excipient manufacturers. As more biologic drugs enter commercial manufacturing phases, the volume requirements for excipients increase substantially, thus contributing to higher market share of commercial-scale operations.

Further, once a formulation is approved, changes to excipients become extremely difficult and costly due to comparability protocols. This creates long-term contracts and preferred supplier relationships, favoring manufacturers with proven large-scale GMP capabilities, robust quality systems, and reliable supply chains. Thus, driving the commercial scale market to grow at a higher CAGR (6.8%) during the forecast period.

Market Share by Type of Modality: Antibodies Segment to Hold the Highest Revenue

Based on the type of modality, the global market is segmented into antibodies, vaccines, cell and gene therapies, proteins / peptides and other biologics.

Presently, antibodies sub-segment is likely to capture majority of the biopharmaceutical excipient manufacturing market size. This is due to their unmatched clinical and commercial dominance among biologics. With hundreds of approved monoclonal antibodies and a robust pipeline across oncology, immunology, and other high-value therapeutic areas, this segment has generated recurring demand for specialized excipients.

Further, mAbs are large, structurally complex proteins inherently prone to physical and chemical instability during manufacturing, storage, shipping, and administration. This necessitates sophisticated excipient systems that go well beyond those required for simpler modalities. Thereby driving the market to grow at a higher CAGR (8.7%) during the forecast period.

Market Share by Source of Manufacturing: In House Segment to Hold the Highest Revenue

On the basis of sources of manufacturing, the global market is segmented into in-house and outsourcing.

According to our projection, in-house manufacturing holds the highest biopharmaceutical excipients market share. This dominance is primarily because excipient quality, traceability, and supply continuity are now viewed as CMC-critical risks that biopharma companies cannot afford to outsource without significant regulatory and operational exposure. Unlike generic bulk excipients, biopharmaceutical-grade excipients must meet stringent purity specifications (low endotoxin, low metal, defined leachables). Any deviation from these specifications can directly compromise protein stability, increase aggregation, and elevate the risk of immunogenicity. As a result, biopharmaceutical sponsors are often reluctant to relinquish control over the supply chain for these critical, high-stakes excipients.

In the coming years, outsourcing is expected to register the highest CAGR during the forecast period within this segment. Outsourcing is gaining strong momentum as it enables sponsors to reduce capital expenditure, achieve economies of scale, and gain flexibility in managing variable demand across pipeline assets without heavy investment in in-house excipient production or testing facilities.

Scope of Biopharmaceutical Excipients Manufacturing Market Report